Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

ZTS Balance Sheet

Assets, liabilities, and equity analysis

ZTS Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Total Current Assets
6.474B6.474B6.768B6.583B5.923B5.877B5.986B6.282B6.202B
1.940B1.940B2.310B2.084B1.435B1.721B1.985B1.710B1.573B
Short-Term Investments
0.000.000.000.000.000.000.000.000.00
Cash & Short-Term Investments
1.940B1.940B2.310B2.084B1.435B1.721B1.985B1.710B1.573B
1.506B1.506B1.590B1.541B1.540B1.361B1.316B1.411B1.383B
2.550B2.550B2.430B2.465B2.439B2.365B2.306B2.416B2.452B
Total Assets
15.154B15.154B15.467B15.159B14.479B14.098B14.237B14.357B14.165B
4.001B4.001B3.969B3.892B3.839B3.661B3.610B3.521B3.422B
2.778B2.778B2.767B2.764B2.758B2.716B2.724B2.744B2.739B
Intangible Assets
959.000M959.000M998.000M1.040B1.075B1.082B1.127B1.186B1.226B
Long-Term Investments
0.000.000.001.000M0.000.0030.000M0.000.00
Total Current Liabilities
2.053B2.053B2.235B1.807B3.366B3.385B3.412B1.702B1.797B
507.000M507.000M487.000M410.000M508.000M420.000M433.000M404.000M420.000M
0.000.0053.000M0.001.350B1.350B1.350B0.000.00
Total Liabilities
11.921B11.921B12.136B9.761B9.502B9.443B9.467B9.123B9.205B
9.045B9.045B9.238B7.069B5.231B5.227B5.220B6.574B6.563B
9.238B9.238B9.493B7.273B6.791B6.750B6.744B6.755B6.744B
Net Debt (Cash)
7.298B7.298B7.183B5.189B5.356B5.029B4.759B5.045B5.171B
Total Shareholders' Equity
3.233B3.233B3.331B5.398B4.977B4.655B4.770B5.234B4.966B
Common Stock
5.000M5.000M5.000M5.000M5.000M5.000M5.000M5.000M5.000M
14.183B14.183B13.744B13.593B12.872B12.375B11.968B11.806B11.124B
3.153.153.033.641.761.741.753.693.45
2.862.862.851.351.361.451.411.291.36

ZTS Annual Balance Sheet (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Current Assets
6.768B5.986B6.343B7.506B6.930B6.611B4.748B4.399B
2.312B1.985B2.039B3.577B3.482B3.602B1.932B1.597B
Short-Term Investments
0.000.000.000.000.000.000.0099.000M
Cash & Short-Term Investments
2.312B1.985B2.039B3.577B3.482B3.602B1.932B1.696B
1.590B1.316B1.304B1.215B1.133B1.013B1.086B1.036B
2.430B2.306B2.564B2.345B1.923B1.628B1.410B1.391B
Total Assets
15.467B14.237B14.286B14.925B13.900B13.609B11.545B10.777B
3.969B3.610B3.434B2.973B2.603B2.394B2.129B1.658B
2.767B2.724B2.759B2.746B2.682B2.694B2.592B2.519B
Intangible Assets
998.000M1.127B1.338B1.380B1.474B1.710B1.890B2.046B
Long-Term Investments
0.0030.000M0.000.000.000.000.000.00
Total Current Liabilities
2.235B3.412B1.889B3.167B1.797B2.170B1.806B1.223B
487.000M433.000M411.000M405.000M436.000M457.000M301.000M313.000M
53.000M1.350B3.000M1.352B0.00604.000M500.000M9.000M
Total Liabilities
12.136B9.467B9.295B10.522B9.356B9.836B8.837B8.592B
9.238B5.220B6.564B6.552B6.592B6.595B5.947B6.443B
9.493B6.744B6.755B8.090B6.743B7.362B6.611B6.452B
Net Debt (Cash)
7.181B4.759B4.716B4.513B3.261B3.760B4.679B4.855B
Total Shareholders' Equity
3.331B4.770B4.997B4.405B4.543B3.769B2.708B2.185B
Common Stock
5.000M5.000M5.000M5.000M5.000M5.000M5.000M5.000M
13.744B11.968B10.295B8.668B7.186B5.659B4.427B3.270B
3.031.753.362.373.863.052.633.60
2.851.411.351.841.481.952.442.95

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck